Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion.

Yeoh KK, Chan MC, Thalhammer A, Demetriades M, Chowdhury R, Tian YM, Stolze I, McNeill LA, Lee MK, Woon ECY, Mackeen MM, Kawamura A, Ratcliffe PJ, Mecinović J, Schofield CJ.

Org Biomol Chem. 2013 Feb 7;11(5):732-745. doi: 10.1039/c2ob26648b. Epub 2012 Nov 15.

2.

Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH).

Flagg SC, Martin CB, Taabazuing CY, Holmes BE, Knapp MJ.

J Inorg Biochem. 2012 Aug;113:25-30. doi: 10.1016/j.jinorgbio.2012.03.002. Epub 2012 Mar 17.

3.

Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology.

Dao JH, Kurzeja RJ, Morachis JM, Veith H, Lewis J, Yu V, Tegley CM, Tagari P.

Anal Biochem. 2009 Jan 15;384(2):213-23. doi: 10.1016/j.ab.2008.09.052. Epub 2008 Oct 14.

PMID:
18952043
4.

Prolyl hydroxylases and therapeutics.

Smith TG, Talbot NP.

Antioxid Redox Signal. 2010 Apr;12(4):431-3. doi: 10.1089/ars.2009.2901.

PMID:
19761407
5.

Differential in vitro and cellular effects of iron chelators for hypoxia inducible factor hydroxylases.

Cho EA, Song HK, Lee SH, Chung BH, Lim HM, Lee MK.

J Cell Biochem. 2013 Apr;114(4):864-73. doi: 10.1002/jcb.24423.

PMID:
23097160
6.

Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases.

Chowdhury R, McDonough MA, Mecinović J, Loenarz C, Flashman E, Hewitson KS, Domene C, Schofield CJ.

Structure. 2009 Jul 15;17(7):981-9. doi: 10.1016/j.str.2009.06.002.

7.

Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2).

McDonough MA, Li V, Flashman E, Chowdhury R, Mohr C, Liénard BM, Zondlo J, Oldham NJ, Clifton IJ, Lewis J, McNeill LA, Kurzeja RJ, Hewitson KS, Yang E, Jordan S, Syed RS, Schofield CJ.

Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9814-9. Epub 2006 Jun 16.

8.

HIF-prolyl hydroxylases and cardiovascular diseases.

Sen Banerjee S, Thirunavukkarasu M, Tipu Rishi M, Sanchez JA, Maulik N, Maulik G.

Toxicol Mech Methods. 2012 Jun;22(5):347-58. doi: 10.3109/15376516.2012.673088. Review.

PMID:
22424133
9.

A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.

Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, Miyata T.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2548-54. Epub 2007 Oct 11.

10.
11.

Studies on the reaction of nitric oxide with the hypoxia-inducible factor prolyl hydroxylase domain 2 (EGLN1).

Chowdhury R, Flashman E, Mecinović J, Kramer HB, Kessler BM, Frapart YM, Boucher JL, Clifton IJ, McDonough MA, Schofield CJ.

J Mol Biol. 2011 Jul 8;410(2):268-79. doi: 10.1016/j.jmb.2011.04.075. Epub 2011 May 13.

PMID:
21601578
12.

Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.

Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM.

J Biol Chem. 2004 Sep 10;279(37):38458-65. Epub 2004 Jul 7.

13.

2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2.

Mecinović J, Loenarz C, Chowdhury R, Schofield CJ.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6192-5. doi: 10.1016/j.bmcl.2009.09.005. Epub 2009 Sep 6.

PMID:
19775891
14.
15.

Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases.

Kanelakis KC, Palomino HL, Li L, Wu J, Yan W, Rosen MD, Rizzolio MC, Trivedi M, Morton MF, Yang Y, Venkatesan H, Rabinowitz MH, Shankley NP, Barrett TD.

J Biomol Screen. 2009 Jul;14(6):627-35. doi: 10.1177/1087057109333976. Epub 2009 Jun 4.

PMID:
19498081
16.

Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1alpha accumulation--implications for prolyl hydroxylase activity and iron.

Callapina M, Zhou J, Schnitzer S, Metzen E, Lohr C, Deitmer JW, Brüne B.

Exp Cell Res. 2005 May 15;306(1):274-84. Epub 2005 Mar 20.

PMID:
15878351
17.

Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.

Spinella F, Rosanò L, Del Duca M, Di Castro V, Nicotra MR, Natali PG, Bagnato A.

PLoS One. 2010 Jun 21;5(6):e11241. doi: 10.1371/journal.pone.0011241.

18.

Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.

Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, Ratan RR.

J Neurosci. 2009 Jul 8;29(27):8828-38. doi: 10.1523/JNEUROSCI.1779-09.2009.

19.

Utilization of an in vivo reporter for high throughput identification of branched small molecule regulators of hypoxic adaptation.

Smirnova NA, Rakhman I, Moroz N, Basso M, Payappilly J, Kazakov S, Hernandez-Guzman F, Gaisina IN, Kozikowski AP, Ratan RR, Gazaryan IG.

Chem Biol. 2010 Apr 23;17(4):380-91. doi: 10.1016/j.chembiol.2010.03.008.

20.

Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.

Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E.

Biochem J. 2004 Aug 1;381(Pt 3):761-7.

Supplemental Content

Support Center